The dynamic biomarker framework underscores that these early-changing core 1 biomarkers are crucial for detecting evolving neurodegenerative changes that are indicative of initial disease stages.8 Notably, the p-tau/Aβ42 ratio has been recognized as a strong predictor of cognitive decline and incident dementia,37 supporting the notion that MBI-related changes might reflect a greater burden of AD neuropathology. The gene discussed is MAPT; the disease is Alzheimer disease.